Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.

Vaccine

Wyeth Vaccines, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA.

Published: August 2009

In 2003, the World Health Organization recommended a concentration of enzyme-linked immunosorbent assay (ELISA) immunoglobulin G (IgG) anti-capsular antibody of 0.35 microg/mL as a reference value that correlates to protection against invasive pneumococcal disease. This threshold can be used to demonstrate immunologic non-inferiority of a new vaccine in comparison trials that use pneumococcal conjugate vaccines (PCVs) as a comparator. An investigational 13-valent PCV (PCV13) compared with seven-valent PCV (PCV7) demonstrated that all of the pneumococcal serotypes contained in PCV13 were immunogenic, with 88-98% of vaccinees achieving antibody concentration > or = 0.35 microg/mL for serotypes shared with PCV7 and >96% for six additional serotypes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.06.008DOI Listing

Publication Analysis

Top Keywords

pneumococcal conjugate
8
035 microg/ml
8
essential criteria
4
criteria evaluation
4
pneumococcal
4
evaluation pneumococcal
4
conjugate vaccine
4
vaccine candidates
4
candidates 2003
4
2003 health
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!